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Pulmonary Fibrosis
The purpose of this poster is to
discuss the pathophysiology of
pulmonary fibrosis. More
specifically, the roles of the
inflammatory and immune
agents thought to be
responsible for stimulating
fibrosis in the lungs will be
discussed. Pulmonary fibrosis
(PF) is a chronic disease of the
lungs involving an altered
inflammatory response to injury
or infection which results in
scarring of lung tissue. The
lungs are then unable to
ventilate or oxygenate
effectively due to the scar tissue.
PF has not been thoroughly
studied compared with many of
the more prevalent diseases
today. PF affects men more
often than women but has seen
an increase in both genders
since 2000. According to Ley
and Collard (2013) the lack of
research in PF is partly due to
the existence of similar
comorbidities such as COPD,
other interstitial lung diseases,
viral infections, etc. and the
unclear definition of PF in the
past.

Signs & Symptoms
The signs and symptoms of PF are
due to the over production of
inflammatory mediators and
proliferation of scar tissue. These
signs and symptoms include,
shortness of breath, dry cough,
fatigue, fever, chest pain, weight
loss, and aching in muscles and
joints (Wilson & Wynn, 2009).

Underlying
Pathophysiology
Normal lung healing takes place
in phases, following the initial injury
is a period of healing that begins
during the acute inflammation and
can take some time to complete.
Depending on the injury and how
much damage is present, the tissue
can regenerate with complete return
to normal function. If the damage
was more severe, resolution is an
acceptable outcome, this is a return
to almost normal. During repair,
scar tissue replaces destroyed tissue.
This type of healing happens with
extensive damage and results in
tissue that is much less viable than it
was before the injury. This
replacement of lung tissue with less
viable tissue causes lung stiffness
and ventilation difficulty. This, in
turn, results in decreased gas
exchange and hypoxemia.

Causes of PF
The injurious agents leading to the
chronic inflammation that precedes
PF may be an environmental,
chemical, or biologic irritant.
Sometimes the cause is unknown such
as in idiopathic pulmonary fibrosis
(IPF). IPF is the most common type of
PF.

Current Research
According to Wilson & Wynn (2009) PFers lack MMP-2 and MMP-9, peptidases
which are required for successful clearance of inflammatory cells. MMP’s help
determine the amount of collagen deposited during healing. Some research has
suggested that the timing of inflammation may be very important in the causation
of lung fibrosis as well. On one hand, research has suggested that inflammation
may not be a factor in PF as anti-inflammatory agents show no improvement.
What’s more, late-stage inflammation may actually improve the risk of scarring by
clearing cell debris and controlling excessive proliferation. This evidence just goes
to show how little is known about PF. (Wilson & Wynn, 2009) On the other hand,
more evidence shows that fibrosis is initiated by the inflammatory response at first
but requires activation of specific pathways to continue collagen production and
contribution to the extracellular matrix, (Wynn & Ramalingam, 2012). This view is
more widely accepted due to the fact that inflammatory mediators are found in
higher concentrations in PF patients; also, a known risk factor of PF is chronic
infections which stimulate inflammation.
Not only do PF patients have excessive inflammatory responses but certain cells in
PF patients have actually shown a heightened sensitivity to some very potent pro
fibrotic cytokines such as IL-13 and TGFbeta1. According to a study on the
responsiveness of fibroblasts, these pro-fibrotic cytokines were shown to interact
with each other to stimulate a fibrotic response more so than one stimulator by
itself, (Murray, Argentieri, Farrell, Bracht, Sheng, Whitaker, Beck, Tsui, Cochlin,
Evanoff, Hogaboam, & Das, 2008)
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Pathophysiology of Fibrosis

According to current research, it is clear that there is not just one factor that
determines the likelihood of developing an altered healing pathway leading to
fibrosis of the lung. Altered responses during the reconstructive phase of healing
lead to increased recruitment of inflammatory and fibrotic mediators such as
cytokines, chemokines, and growth factors. Much of the literature confirms that
these mediators are increased in patients with pulmonary fibrosis (PF).
Following injury, lung epithelial cells are turned on to signal TGFbeta1 induced
expression of connective tissue growth factor (CTGF). CTGF is a pro-fibrotic
cytokine that is indicated in fibroblast activation which “express/contribute to the
fibrotic matrix proteins and induce further expression of pro-fibrotic cytokines,
resulting in progressive fibrosis and establishment of ECM (extra-cellular matrix).”
(Wilson & Wynn, 2009). Chronic inflammation exposes one to develop fibrosis and
to turn on pro-fibrotic mediators more readily. The proliferation and recruitment of
platelets, degranulation, clots, and leukocytes along with the ECM, contribute to the
blocking of the damaged endothelium from resolution.
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Significance of Pathophysiology
Differing research findings suggest that there is still much more to be discovered
of the pathophysiology of PF. Current understanding of the pathophysiology is
important for healthcare providers to know in order to determine diagnostic criteria.
Early and accurate diagnosis greatly influences implementation of an effective
treatment plan. Knowing the specific pathophysiology is especially important when
determining the treatment plan for patients with PF. Healthcare providers must
know specifics in disease stages, inflammatory mediator presence, and what these
mediators indicate regarding the unique sequence of that patient’s condition.
Knowing the pathophysiology aids critical thinking and clarifies understanding of
when and why therapies and medications work.

Conclusion

Nursing Implications

•

Nurses must know the
pathophysiology in order to
educate PF patients regarding
their treatments,
medications, and changes in
lifestyle.
A more thorough
understanding of the possible
contributing factors can allow
the bedside nurse to act as an
extra filter when checking for
treatment and medication
contraindications.
There is evidence that certain
biologic agents that are used
as treatments and therapies
can contribute to PF. One
example exists with a study
of anti-tumor necrosis factor
given as a treatment for
rheumatoid arthritis. Of the
cases studied, 16% of
patients developed lung
fibrosis, (Perez-Alvarez,
Perez-de-Lis, Diaz-Lagares,
Pego-Reigosa, Retamozo, &
Bove, 2014).
Nurses must know the
efficacy of the treatments
they are administering for PF
patients.
Nurse Practitioners (NP’s),
specifically, must know
diagnostic criteria and
variables in disease
presentation.
Healthcare providers must
keep up on new research.
For example, molecular
biomarkers show some
promise in evaluating a
patient based on their stage
of PF and their specific
responses and activated
pathways regarding
inflammation and fibrosis.
This research, however, is
underpowered and is lacking
in validation at this time,
(Hambly, Shimbori, & Kolb,
2015).
It is important for NP’s, as
leaders in healthcare, to be
aware of current research to
aid in accurate diagnoses
and development the most
effective treatment plans.
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Pulmonary fibrosis is a lung
disorder characterized by
development of a fibrotic
pathway following injury and
inflammation.
Initial injury can be caused by
environmental, biologic, or
chemical irritants. Many times
the cause is unknown.
Lung fibrosis leads to difficult
ventilation and perfusion and
subsequent hypoxemia.
Current research shows an
increase in inflammatory
mediators which stimulate ECM
deposition.
Much research is incomplete or
conflicting; this indicates a need
for further investigation.
Knowledge of pathophysiology
and current research is crucial
for healthcare providers in order
to guide their treatment.
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